Search research articles
Contact Us
Filters
Showing results (191-200 of 233) with videos related to
Page
of 24
Sort By:
European Journal of Medicinal Chemistry
|
October 14, 2015
2-Aminopyrimidines as dual adenosine A1/A2A antagonists
Sarel J Robinson, Jacobus P Petzer, Gisella Terre'Blanche, et al.
International Journal of Cancer
|
March 1, 1994
Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients
P Nygren, H Fridborg, K Csoka, et al.
Breast Cancer Research and Treatment
|
September 20, 2001
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
K S Hall, T Wiklund, B Erikstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 1998
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401
J Bergh, T Wiklund, B Erikstein, et al.
International Journal of Cancer
|
April 15, 1987
Expression of multiple growth factors in a human lung cancer cell line
C Betsholtz, J Bergh, M Bywater, et al.
Genomics
|
January 1, 1991
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer
M C Daly, J B Douglas, N M Bleehen, et al.
Bioorganic & Medicinal Chemistry
|
April 10, 2007
Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues
Deidré van den Berg, Kevin R Zoellner, Modupe O Ogunrombi, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 1, 1996
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53
T Norberg, T Jansson, S Sjøgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2005
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
J Andersson, L Larsson, S Klaar, et al.
Bone Marrow Transplantation
|
September 11, 1998
High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer
P Ljungman, B Björkstrand, T Fornander, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 233) with videos related to
Sort By:
Page
of 24
European Journal of Medicinal Chemistry
|
October 14, 2015
2-Aminopyrimidines as dual adenosine A1/A2A antagonists
Sarel J Robinson, Jacobus P Petzer, Gisella Terre'Blanche, et al.
International Journal of Cancer
|
March 1, 1994
Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients
P Nygren, H Fridborg, K Csoka, et al.
Breast Cancer Research and Treatment
|
September 20, 2001
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
K S Hall, T Wiklund, B Erikstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 1998
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401
J Bergh, T Wiklund, B Erikstein, et al.
International Journal of Cancer
|
April 15, 1987
Expression of multiple growth factors in a human lung cancer cell line
C Betsholtz, J Bergh, M Bywater, et al.
Genomics
|
January 1, 1991
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer
M C Daly, J B Douglas, N M Bleehen, et al.
Bioorganic & Medicinal Chemistry
|
April 10, 2007
Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues
Deidré van den Berg, Kevin R Zoellner, Modupe O Ogunrombi, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 1, 1996
Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53
T Norberg, T Jansson, S Sjøgren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2005
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
J Andersson, L Larsson, S Klaar, et al.
Bone Marrow Transplantation
|
September 11, 1998
High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer
P Ljungman, B Björkstrand, T Fornander, et al.
Page
of 24